NCT05293496 is a Phase 1 clinical trial of vobramitamab duocarmazine in Advanced Solid Tumor, sponsored by MacroGenics.

Who is sponsoring NCT05293496?

NCT05293496 is sponsored by MacroGenics.

What drugs are being tested in NCT05293496?

Interventions in NCT05293496: vobramitamab duocarmazine, lorigerlimab.

What condition does NCT05293496 study?

NCT05293496 studies Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma.

Is NCT05293496 still recruiting?

NCT05293496 is currently completed. Last updated 14 October 2025.

Last reviewed 2025-10-14 · How we verify

NCT05293496

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Completed Phase 1 Last updated 14 October 2025

What this trial tests

Phase 1 trial testing vobramitamab duocarmazine in Advanced Solid Tumor in 31 participants. Completed in 26 August 2025.

Timeline

19 April 2022

Primary endpoint
24 June 2025

26 August 2025

Quick facts

Lead sponsor	MacroGenics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	19 April 2022
Primary completion	24 June 2025
Estimated completion	26 August 2025
Sites	10 locations across United States

Drugs / interventions tested

vobramitamab duocarmazine — full drug profile →
lorigerlimab — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Castration-Resistant Prostatic Cancer — all drugs for Castration-Resistant Prostatic Cancer →
Malignant Melanoma — all drugs for Malignant Melanoma →
Pancreatic Ductal Carcinoma — all drugs for Pancreatic Ductal Carcinoma →

Sponsor

MacroGenics — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumor or Castration-Resistant Prostatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled. Vobramitamab duocarmazine and lorigerlimab are administered separately on Day 1 of every 4-week (28-day) cycle at the assigned dose for each cohort. Participants who do not meet criteria for study drug discontinuation may receive study drugs for up to 2 years. Tumor assessments are performed every 8 weeks (± 7 days) for the initial 6 months on study drugs, then every 12 weeks (± 21 days) until progressive disease (PD). Participants will be followed for safety throughout the study. .

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.
Cheng W, Kang K, Zhao A, Wu Y. · · 2024 · cited 110× · PMID 39068460 · DOI 10.1186/s13045-024-01581-2
Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease.
Wong HY, Sheng Q, Hesterberg AB, Croessmann S, et al · · 2022 · cited 104× · PMID 36229464 · DOI 10.1038/s41467-022-33780-1
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.
Wei Q, Li P, Yang T, Zhu J, et al · · 2024 · cited 102× · PMID 38178200 · DOI 10.1186/s13045-023-01509-2
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment.
Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, et al · · 2023 · cited 58× · PMID 37345056 · DOI 10.3390/cancers15102718
The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer.
Xu P, Wasielewski LJ, Yang JC, Cai D, et al · · 2022 · cited 29× · PMID 35892678 · DOI 10.3390/biomedicines10081778
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
Zhou L, Lu Y, Liu W, Wang S, et al · · 2024 · cited 27× · PMID 38429828 · DOI 10.1186/s40164-024-00493-8
New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.
Koumprentziotis IA, Theocharopoulos C, Foteinou D, Angeli E, et al · · 2024 · cited 26× · PMID 38250867 · DOI 10.3390/vaccines12010054

Verify or expand the search:

Other trials of vobramitamab duocarmazine

Trials testing the same drug.

NCT05551117 — A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Soli · Phase 2 · terminated
NCT03729596 — MGC018 With or Without MGA012 in Advanced Solid Tumors · Phase 1, PHASE2 · terminated

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Other MacroGenics trials

Trials by the same sponsor.

NCT05848011 — A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate · Phase 2 · completed
NCT05551117 — A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Soli · Phase 2 · terminated
NCT05261191 — A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy · Phase 1 · completed
NCT04634825 — Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer · Phase 2 · terminated
NCT04082364 — Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05293496 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MacroGenics
Last refreshed: 14 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05293496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing